WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Wnt/β-catenin (WβC) signaling pathway is an important signaling pathway for the maintenance of cellular homeostasis from the embryonic developmental stages to adulthood. The canonical pathway of WβC signaling is essential for neurogenesis, cell proliferation, and neurogenesis, whereas the noncanonical pathway (WNT/Ca2+ and WNT/PCP) is responsible for cell polarity, calcium maintenance, and cell migration. Abnormal regulation of WβC signaling is involved in the pathogenesis of several neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and spinal muscular atrophy (SMA). Hence, the alteration of WβC signaling is considered a potential therapeutic target for the treatment of neurodegenerative disease. In the present review, we have used the bibliographical information from PubMed, Google Scholar, and Scopus to address the current prospects of WβC signaling role in the abovementioned neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · cited 1×
“The mutations on the Huntington gene on chromosome 4 are mainly responsible for the development of HD [161].”
BackgroundNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“The interaction of pattern recognition receptors in glial cells and astrocytes triggers the innate immune response cells to release inflammatory mediators, which further extent and progress AD [87,88].”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 1×
“Therefore, during the management of ALS, occupational therapy, physical therapy, respiratory therapy, social work, nursing, and dietary therapy can be provided to ALS patients [188].”
BackgroundStructure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185 · cited 1×
“The BBB protects the brain from external neurotoxic agents such as microbes, cells, and blood-derived harmful substances [77,78].”
BackgroundZhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875 · cited 2×
“Astrocytes release WNT 7a (anti-aggregate tau mutant) and activate WβC signaling, thereby enhancing the neurogenesis in AD [67,68].”
BackgroundWnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437 · cited 1×
“The BBB protects the brain from external neurotoxic agents such as microbes, cells, and blood-derived harmful substances [77,78].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519 · cited 2×
“The nuclear segment mainly includes β-catenin, TCF/LEF family members, and β-catenin downstream target genes, such as matrix metalloproteinases (MMPs) and c-Myc activation [6,10].”
BackgroundSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 1×
“Pulmonary, gastrointestinal, and orthopedic supportive care [249–251], along with drugs like nusinersen [252], onasemnogene abeparvovec [253], risdiplam [254], and botulinum toxin [255], are used for the treatment of SMA.”
BackgroundSynapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · cited 1×
“Early stages of AD are associated with synaptic loss and have a strong impact on learning and memory behavior [52].”
BackgroundNusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337 · cited 1×
“Pulmonary, gastrointestinal, and orthopedic supportive care [249–251], along with drugs like nusinersen [252], onasemnogene abeparvovec [253], risdiplam [254], and botulinum toxin [255], are used for the treatment of SMA.”
BackgroundNon-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
Dynamics of hippocampal neurogenesis in adult humans
Spalding, K. L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H. B., Boström, E., Westerlund, I., Vial, C., Buchholz, B. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.002 · Cited by 1,841
Wnt signal transduction pathways
Komiya, Y., & Habas, R. (2008) · Organogenesis · doi:10.4161/org.4.2.5851 · Cited by 1,528 · cited 1×
“Additionally, ROCK and JNK1 promote actin in the cytoskeleton which plays a crucial role in the cell proliferation [13].”
BackgroundTargeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191 · cited 2×
“GSK-3β is known to phosphorylate the β-catenin and promote its degradation [92].”
BackgroundThe -Catenin Destruction Complex
Stamos, J. L., & Weis, W. I. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007898 · Cited by 1,062 · cited 1×
“Therefore, this cytosolic β-catenin translocates to the nucleus, where it interacts with TCF/LEF, thereby regulating the different functions [20,21].”
BackgroundAPP processing in Alzheimer’s disease.
Zhang, Y.-W., Thompson, R., Zhang, H., & Xu, H. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-3 · Cited by 983
Wnt/β-catenin signaling controls development of the blood–brain barrier
Liebner, S., Corada, M., Bangsow, T., Babbage, J., Taddei, A., Czupalla, C. J., Reis, M., Felici, A., Wolburg, H., Fruttiger, M., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806024 · Cited by 860 · cited 1×
“These WNT ligands activate the WβC pathway in endothelial cells (EC) through upregulating tight junction proteins such as claudin 1, 3, and 5, which enables the formation of connections between multiple cells, which results in BBB formation and maintains its integrity [68,84].”
BackgroundWnt/β-catenin signaling is required for CNS, but not non-CNS, angiogenesis
Daneman, R., Agalliu, D., Zhou, L., Kuhnert, F., Kuo, C. J., & Barres, B. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805165106 · Cited by 753
Wnt and calcium signaling: β-Catenin-independent pathways
Kohn, A. D., & Moon, R. T. (2005) · Cell Calcium · doi:10.1016/j.ceca.2005.06.022 · Cited by 730 · cited 2×
“WNT-dependent increases in Ca2+ levels are achieved either by inhibiting cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG), which prevents Ca2+ release in unstimulated cells or by activating phospholipase C (PLC), which raises inositol 1,4,5-triphosphate (IP3) [15].”
BackgroundWnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis
Kuwabara, T., Hsieh, J., Muotri, A., Yeo, G., Warashina, M., Lie, D. C., Moore, L., Nakashima, K., Asashima, M., & Gage, F. H. (2009) · Nature Neuroscience · doi:10.1038/nn.2360 · Cited by 648
Ishitani, T., Ninomiya-Tsuji, J., Nagai, S.-I., Nishita, M., Meneghini, M., Barker, N., Waterman, M., Bowerman, B., Clevers, H., Shibuya, H., et al. (1999) · Nature · doi:10.1038/21674 · Cited by 621 · cited 1×
“CamKII promotes transform growth factor-β (TGF-β)-activated kinase (TAK1) and Nemo-like kinase (NEMO), which can phosphorylate and inactivate TCF and inhibit WβC signaling [16,17].”
BackgroundKang, S. H., Li, Y., Fukaya, M., Lorenzini, I., Cleveland, D. W., Ostrow, L. W., Rothstein, J. D., & Bergles, D. E. (2013) · Nature Neuroscience · doi:10.1038/nn.3357 · Cited by 599 · cited 1×
“In regenerated oligodendrocytes, WβC activation leads to delayed maturation, impairment in myelin repair efficiency, formation of immature myeline sheaths, and inflamed myelin sheaths, eventually leading to non-myelinating oligodendrocytes [211,212].”
BackgroundNew insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
Wayman, G. A., Impey, S., Marks, D., Saneyoshi, T., Grant, W. F., Derkach, V., & Soderling, T. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.008 · Cited by 466 · cited 2×
“ment-binding protein (CREB) mediated transcription process [19]—owing to multiple physiological and pathological roles, particularly cell proliferation, survival, and migration.”
BackgroundInhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442
Role of the Blood–Brain Barrier in Multiple Sclerosis
Ortiz, G. G., Pacheco-Moisés, F. P., Macías-Islas, M. Á., Flores-Alvarado, L. J., Mireles-Ramírez, M. A., González-Renovato, E. D., Hernández-Navarro, V. E., Sánchez-López, A. L., & Alatorre-Jiménez, M. A. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.11.013 · Cited by 373 · cited 1×
“Dysregulation of BBB enhances the permeability and neutrophil infiltration in MS [240].”
BackgroundPathogenesis of Parkinson's disease
Hirsch, E. C., Jenner, P., & Przedborski, S. (2013) · Movement Disorders · doi:10.1002/mds.25032 · Cited by 336 · cited 1×
“Several research studies indicate that PD patients diagnosed with these motor impairments are also found with reduced DA levels, increased accumulation of α-synuclein, and Lewy bodies formations which are considered diagnostic hall markers of PD [125].”
BackgroundActivity-dependent synaptic Wnt release regulates hippocampal long term potentiation
Chen, J., Park, C. S., & Tang, S.-J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511920200 · Cited by 298 · cited 1×
“WNT proteins modulate neuronal transmission at pre and post-synapse by promoting LTP, thereby beginning synapse formation [53].”
BackgroundRestoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease
Jia, L., Piña-Crespo, J., & Li, Y. (2019) · Molecular Brain · doi:10.1186/s13041-019-0525-5 · Cited by 288
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, B.-E., Henjum, K., Selnes, P., Gísladóttir, B., Wettergreen, M., Torsetnes, S. B., Grøntvedt, G. R., Waterloo, K. K., Aarsland, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1399-2 · Cited by 274
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270 · cited 1×
“The current treatment for AD is the administration of choline esterase inhibitors, n-methyl-D-asprtate (NMDA) antagonists, and choline esterase inhibitors such as donepezil, galantamine, and rivastigmine [42].”
BackgroundFemale Sex and Alzheimer's Risk: The Menopause Connection
Scheyer, O., Rahman, A., Hristov, H., Berkowitz, C., Isaacson, R. S., Diaz Brinton, R., & Mosconi, L. (2018) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.34 · Cited by 268
Zhou, Y., & Nathans, J. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.08.018 · Cited by 265 · cited 1×
“WβC activators such as WNT 7a/WNT 7b regulate the BBB formation and integrity and CNS angiogenesis via Reck and Gpr124 proteins [83].”
BackgroundLim, R. G., Quan, C., Reyes-Ortiz, A. M., Lutz, S. E., Kedaigle, A. J., Gipson, T. A., Wu, J., Vatine, G. D., Stocksdale, J., Casale, M. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.021 · Cited by 253
Ortega, F., Gascón, S., Masserdotti, G., Deshpande, A., Simon, C., Fischer, J., Dimou, L., Chichung Lie, D., Schroeder, T., & Berninger, B. (2013) · Nature Cell Biology · doi:10.1038/ncb2736 · Cited by 247 · cited 2×
“Oligodendrocyte development during physiological and pathological conditions is driven by WβC signaling [213].”
BackgroundLiu, C.-C., Tsai, C.-W., Deak, F., Rogers, J., Penuliar, M., Sung, Y. M., Maher, J. N., Fu, Y., Li, X., Xu, H., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.048 · Cited by 222 · cited 5×
“Moreover, postnatal deletion of LRP6 activates microglia and neuroinflammation in AD [57].”
BackgroundInfluentialTran, K. A., Zhang, X., Predescu, D., Huang, X., Machado, R. F., Göthert, J. R., Malik, A. B., Valyi-Nagy, T., & Zhao, Y.-Y. (2016) · Circulation · doi:10.1161/circulationaha.115.015982 · Cited by 219
The secreted Wnt antagonist Dickkopf-1 is required for amyloid β-mediated synaptic loss
Purro, S. A., Dickins, E. M., & Salinas, P. C. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4562-11.2012 · Cited by 195 · cited 1×
“Further, treatment with DKK1-neutralizing antibodies [75] reduces the risk of AD.”
BackgroundEndothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis
Lengfeld, J. E., Lutz, S. E., Smith, J. R., Diaconu, C., Scott, C., Kofman, S. B., Choi, C., Walsh, C. M., Raine, C. S., Agalliu, I., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609905114 · Cited by 152
Effect of Chlorogenic Acid Supplementation in MPTP-Intoxicated Mouse
Singh, S. S., Rai, S. N., Birla, H., Zahra, W., Kumar, G., Gedda, M. R., Tiwari, N., Patnaik, R., Singh, R. K., & Singh, S. P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00757 · Cited by 125
Self-citationImpaired Wnt Signaling in the Prefrontal Cortex of Alzheimer’s Disease
Folke, J., Pakkenberg, B., & Brudek, T. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1103-z · Cited by 123 · cited 1×
“AD patients were diagnosed with enhanced GSK3β activity [93].”
BackgroundA Role for P-Glycoprotein in Clearance of Alzheimer Amyloid ? -Peptide from the Brain
Wang, W., M. Bodles-Brakhop, A., & W. Barger, S. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314151012 · Cited by 107
Lrp4 in astrocytes modulates glutamatergic transmission
Sun, X.-D., Li, L., Liu, F., Huang, Z.-H., Bean, J. C., Jiao, H.-F., Barik, A., Kim, S.-M., Wu, H., Shen, C., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4326 · Cited by 102
Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells
Caruso, A., Motolese, M., Iacovelli, L., Caraci, F., Copani, A., Nicoletti, F., Terstappen, G. C., Gaviraghi, G., & Caricasole, A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03867.x · Cited by 101 · cited 1×
“It has been reported that dysregulation and malfunction of WNT co-receptor, LRP6 is associated with the development of AD in multiple ways, including inhibition of LRP6 expression by APOE4, decreased LRP6 interaction with APP promotes Aβ production and splicing of LRP6 by single nucleotide polymorphisms (SNPs) [57,71,…”
BackgroundPharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022) · Cells · doi:10.3390/cells12010131 · Cited by 96
Dengler-Crish, C. M., Ball, H. C., Lin, L., Novak, K. M., & Cooper, L. N. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.021 · Cited by 58
Anderegg, A., Lin, H.-P., Chen, J.-A., Caronia-Brown, G., Cherepanova, N., Yun, B., Joksimovic, M., Rock, J., Harfe, B. D., Johnson, R., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003973 · Cited by 57 · cited 1×
“MIR-135A2 and LIM homeobox transcription factor 1-beta (LMX1B) modulate WNT1/WNT signaling, thereby maintaining the midbrain DAergic progenitor pool [147,148] through regulating and dicer gene.”
Cited by
Gupta, A. K., Gupta, S., Mehan, S., Khan, Z., Das Gupta, G., & Narula, A. S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05001-5 · Cited by 59
LncRNAs Orchestrating Neuroinflammation: A Comprehensive Review
Esmaeili, A., Yazdanpanah, N., & Rezaei, N. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01538-0 · Cited by 24
Rouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20
“These disorders encompass a broad spectrum of diseases with deep-seated and severe symptoms, including Alzheimer ’ s disease (AD), Parkinson ’ s disease (PD), Huntington ’ s disease (HD), and other brain disorders [1, 4 – 6].”
Background
Metadata
- Authors
- Ramakrishna, K., Nalla, L. V., Naresh, D., Venkateswarlu, K., Viswanadh, M. K., Nalluri, B. N., Chakravarthy, G., Duguluri, S., Singh, P., Rai, S. N., Kumar, A., Singh, V., & Singh, S. K.
- Venue
- Diseases
- Publisher
- MDPI AG
- Published
- 2023-06-25
- Volume
- 11
- Issue
- 3
- Pages
- 89
- ISSN
- 2079-9721 (ISSN-L)
- OpenAlex
- W4382141546
- Cited by
- 192
- References
- 56
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.